Skystar Bio-Pharmaceutical Company
Skystar Bio-Pharmaceutical — Investor Presentation (July 2009)
24 slides from Skystar Bio-Pharmaceutical's investor presentation, Jul 31, 2009

Slide 1: Skystar Bio-Pharmaceutical Co., Ltd.
Paid SKYSTAR ped Bio-PHARMACEUTICAL CO.,LTD. SKYSTAR Weibing Lu, Chairman and CEO R. Scott Cramer, Director Bennet P, Tchaikovsky, CFO

Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation may be "Tforwarc-looking statements" within the meaning of federal securities laws. The matters discussed herein that are forward-looking statements are based on current management expectations that involve risks and uncertainties thet may result

Slide 3: Company Overview
Company Overview Leading China-based producer and distributor of veterinary medicines, vaccines, microorganisms and feed additives -GMP production facilities and processes «Headquartered in Xi’an, Shaanxi Province, China -216 employees -Only U.S. listed veterinary supply in China

Slide 4: 2009 Recent Events
2009 Recent Events Completed public offering for 1.61M shares of common i _ Stock for gross proceeds of ~$21.0M Began trading on NASDAQ under the symbol “SKBI” Use of Proceeds: Construction of new facilities, research and development, marketing, working capital Presided over the Nasdaq Opening Bell

Slide 5: Why Invest in Skystar
Why Invest in Skystar » Leader in young, fragmented industry where demand exceeds supply > Compelling market opportunity estimated at more than $7B » Extensive product lines covering all key animal farming industry segments » Established sales and distribution network to direct customers in all farm

Slide 6: Growing Industry
Growing Industry Consolidation of family owned/operated farms and improved technology are driving demand and growth in the veterinary industry > China is the world’s largest producer of poultry and livestock >» Government supports rapid development of modernization > Disease prevention, vaccines and

Slide 7: Products Lines Address Major Industry Segments
Products Lines Address Major Industry Segments : ] GrossMargin Veterinary Medications $17,535,757 68%| $ 7,146,034 56% Micro-organism $ 5,868,623 23% | $ 4,087,025 32% Feed Additives $ 1,189,108 5%| $ 663,455 5% Veterinary Vaccines $ 990,958 4%| $ 879,039 Th Total $25,584,446 100% | $12,775,550 100%

Slide 8: Veterinary Medications
Veterinary Medications Year ended 12/31/08 as a Percentage of Total Veterinary Medications $17,535,757 68% | $ 7,146,031 56% Total $25,584,446 100% | $12,775,550 100% 140 products > 34 drugs approved in 2008 > Target: 40 drug approvals in 2009

Slide 9: Micro-organism
Micro-organism Year ended 12/31/08 as a Percentage of Total Micro-organism $ 5,868,623 23% | $ 4,087,025 32% Total $25,584,446 100% | $12,775,550 100% 13 products » In house production of microbial strains significantly reduced production costs in 2008 » Constructing new production facility to incre

Slide 10: Feed Additives
Feed Additives Year ended 12/34/08 as a Percentage of Total Feed Additives $ 1,189,108 5% | $ 663,455 5% Total $25,584,446 100% | $12,775,550 100% 10 products >» Increase yield >» Improve health of livestock SkusTaR Wl Bo Pranmaceurea. co.Lmo 10

Slide 11: Veterinary Vaccines
Veterinary Vaccines Year ended 12/31/08 as a Percentage of Total Veterinary Vaccines $ 990,958 4% | $ 879,039 ™% Total $25,584,446 100% | $12,775,550 100% 10 products (active and inactive) » Constructing new production facility to increase production capacity by 2,300% > Initiate production 4Q09; ta

Slide 12: Effective R&D Capabilities
Effective R&D Capabilties Over 25 researchers responsible for developing new medicines and vaccines in tesponse to epidemics, pandemics and diseases Two Labs: Veterinary Medicine Lab and Microorganism Lab) One Quality Inspection Center S researchers from the Chinese Academy of Agricultural Sciences

Slide 13: Bringing Products to Market
Bringing Products to Market Launched several products targeting porcine reproductive and respiratory syndrome (PRRS), aka Blue Ear Disease >» April, 2007: launched Chinese Goldthread (Huanglian) Detoxification Powder ("CGDP") » July, 2007: launched First Aid Kit for Swine High Fever Syndrome » Cures

Slide 14: Customers and Distribution
Customers and Distribution “4

Slide 15: Skystar's Competitive Advantages
Skystar’s Competitive Advantages Only US, listed veterinary supply in China Largest competitors Majority of are State-owned competitors only offer Enterprises 1-2 product lines Established over 350 High barriers of entry franchise stores in for international 2007-2008 competitors Distribution networ

Slide 16: Growth Strategy
Growth Strategy + 40 new product introductions planned for 2009 + Covers all four product lines * Leverage R&D capabilities to continue to add to portfolio and increase market share Commercialize New Products Ex pan d + Two new facilities scheduled for completion in 4Q09 Manufacturing ff Build out i

Slide 17: Annual Revenue Growth
Annual Revenue Growth $30.00 $25.58 $25.00 $20.00 $15.10 $15.00 9.80 $10.00 d ia 1) $5.00 $4.00 $1.20 L] $0.00 + 2003 2004 2006 2007 2008 Revenue ($MM) (9 Bo PranmuceuTeaL.co.LT0.

Slide 18: 1Q 2009 Revenue Growth
1Q 2009 Revenue Growth $4.00 $3.82 $3.00 $2.69 2009 18

Slide 19: Annual Gross Margin Expansion
Annual Gross Margin Expansion $14.00 $12.00 $10.00 $8.00 $6.00 $4.00 $2.00 $0.00 + $0.60 = $3.00 Oo a | 1% 2003 2005 2007 2008 ima Gross Margin (SMM) =* Gross Margin (%) SkusTaR Bo Pranmaceumcat co... 19

Slide 20: 1Q09 Margin Expansion
1Q09 Margin Expansion $3.00 $2.50 490% ON —___,. 49, s0%f 50.0% $2.00 $1.88 40.0% $1.50 $1.39 30.0% $1.00 20.0% $0.67 $0.50 | 10.0% $0.00 + + 0.0% 2007 2008 2009 lm Gross Margin ($MM) —*— Gross Margin (%) SkusTaR Bo Pranmaceumcat co... Et)

Slide 21: High Margin Products
High Margin Products Veterinary Medications Micro-organism Feed Additives Vaccines Total 12 Months Ended 12/31/08 $25,584,446 $12,7 Revenues Gross GM % Margin $17,535,757 | $7,146,031 41% 5,868,623 | 4,087,025 70% 1,189,108 663,455 56% 990,958 879,039 89% a

Slide 22: Annual Adjusted Net Income Growth
Annual Adjusted Net Income Growth $7.00 + $6.00 $5.00 $4.00 $3.00 $2.00 $1.00 $0.00 30.0% p.2% 25.0% 20.0% 15.0% 10.0% 5.0% 0.0% 2003 2004 2005 2006 2007 [ EE Net Income ($MM) —e—Profit Margin Ee Bo Panmacaren ea Le. 2008 2

Slide 23: Seasoned Management
Seasoned Management Weibing Lu Wei Wen Bennet P. Tchaikovsky Erna Gao R. Scott Cramer Chairman and CEO. Director and Vice General Manager CFO VP Finance & Administration Director Founder: Xian Tianxing Bio- Pharmaceutical Co. Awarded Outstanding Entrepreneur of Xi'an Feed Industry Director of Xi'an

Slide 24: Why Invest in Skystar
Why Invest in Skystar » Leader in young, fragmented industry where demand exceeds supply > Compelling market opportunity estimated at more than $7B » Extensive product lines covering all key animal farming industry segments » Established sales and distribution network to direct customers in all farm
Source: SEC EDGAR · 8-K filed Jul 31, 2009
More decks from Skystar Bio-Pharmaceutical Company
RENN Investor Conference, May 14, 201037 slides · May 17, 2010
Investor Presentation (March 2010)41 slides · Mar 17, 2010
Investor Presentation (March 2010)34 slides · Mar 8, 2010
Investor Presentation (November 2009)40 slides · Nov 20, 2009
Investor Presentation (October 2009)30 slides · Oct 14, 2009
Investor Presentation (September 2009)43 slides · Sep 9, 2009